American Society of Hematology (ASH) 2020
Real-World Eculizumab Dosing Patterns Among Patients With Paroxysmal Nocturnal Hemoglobinuria In A US Population
Comparative Effectiveness Of Pegcetacoplan Versus Ravulizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated With Eculizumab: A Matching-Adjusted Indirect Comparison
Real-World Treatment Patterns And Healthcare Resource Utilization (HRU) Of Patients (Pts) With Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab In A US Population
Results Of The PEGASUS Phase 3 Randomized Trial Demonstrating Superiority Of The C3 Inhibitor, Pegcetacoplan, Compared To Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria
Categorized Hematologic Response To Pegcetacoplan Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis Of Data From A Phase 3 Randomized Trial (PEGASUS)
Pegcetacoplan Is Superior To Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria Regardless Of Prior Transfusion Requirement
Effect Of Pegcetacoplan On Quality Of Life In Patients With Paroxysmal Nocturnal Hemoglobinuria From The Pegasus Phase 3 Trial Comparing Pegcetacoplan To Eculizumab
C3 Inhibition With Pegcetacoplan In Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From The Paddock And Palomino Trials
Work Productivity Loss And Quality Of Life In Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors In The United States
Clinical Burden Of Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors In The United States
Improvements In Fatigue Correlate With Changes In Clinical And Hematological Outcomes: Post Hoc Analyses From The Pegasus Study